NCT06888362 2026-01-28
Trial to Investigate GZ21T in Healthy Volunteers
Genzada Pharmaceuticals USA, Inc.
Phase 1 Completed
Clinical Trials
105 trialsNCT06027619 2025-10-23
Short Contact Protocols to Reduce Pain During 10% ALA Gel Red-light Photodynamic Therapy of Actinic Keratoses
Case Comprehensive Cancer Center
Phase 2 Completed
NCT02373371 2025-07-29
Actinic Keratoses Treatment With Metvix® in Combination With Light
University Hospital, Limoges
Phase 3 Completed
NCT00472459 2025-04-18
Photodynamic Therapy (PDT) With Metvix® 160 Milligrams/Gram Cream in Organ Transplant Participants With Non-melanoma Skin Cancer
Galderma R&D
Phase 3 Completed
NCT01820260 2025-03-13
Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Keratosis
LEO Pharma
Phase 1/2 Completed
NCT02549352 2025-03-13
Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up
LEO Pharma
Phase 3 Completed
NCT03115476 2025-03-11
A Trial to Compare the Incidence of Squamous Cell Carcinoma (SCC) and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
LEO Pharma
Phase 3 Terminated
NCT01541553 2025-03-10
A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp
LEO Pharma
Phase 3 Completed
NCT01600014 2025-03-10
Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp
LEO Pharma
Phase 3 Completed
NCT01998984 2025-03-10
Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis
LEO Pharma
Phase 2 Completed
NCT02305888 2025-03-10
Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively
LEO Pharma
Phase 2 Completed
NCT02361216 2025-03-10
Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest
LEO Pharma
Phase 3 Completed
NCT02547233 2025-03-10
Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up
LEO Pharma
Phase 3 Completed
NCT02547363 2025-03-10
Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up
LEO Pharma
Phase 3 Completed
NCT02549339 2025-03-10
Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up
LEO Pharma
Phase 3 Completed
NCT01449513 2025-03-07
PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy
LEO Pharma
Phase 1 Completed
NCT01926496 2025-03-07
Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%
LEO Pharma
Phase 4 Completed
NCT01922050 2025-03-06
A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis
LEO Pharma
Phase 1/2 Completed
NCT02100813 2025-03-06
Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis
LEO Pharma
Phase 1/2 Completed
NCT02120456 2025-03-06
Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis
LEO Pharma
Phase 1/2 Completed
NCT01787383 2025-02-24
A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities
LEO Pharma
Phase 3 Completed
NCT05741294 2025-02-20
A Study of Tirbanibulin on the Wellbeing of Participants With Actinic Keratoses
Almirall, S.A.
Phase 4 Completed
NCT03643744 2024-12-19
Photodynamic Therapy-Induced Immune Modulation: Part III
Wright State University
Phase 1 Terminated
NCT05365386 2024-12-03
Efficacy and Safety of Tixel Treatment on Facial and/or Scalp Actinic Keratoses.
Novoxel Ltd.
Phase NA Completed
NCT05060237 2024-10-17
Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp
Biofrontera Bioscience GmbH
Phase 1 Completed
NCT03327831 2024-06-27
Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses
University of California, Irvine
Phase 4 Completed
NCT05279131 2024-01-23
A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis
Almirall, S.A.
Phase 3 Completed
NCT04269395 2023-10-10
A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study
Galderma R&D
Phase 3 Terminated
NCT01966120 2023-07-28
Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis (AK) With Photodynamic Therapy (PDT)
Biofrontera Bioscience GmbH
Phase 3 Completed
NCT00304239 2023-07-03
Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp
Galderma R&D
Phase 3 Completed
NCT03483935 2023-03-06
MTAK
University of Dundee
Phase NA Completed
NCT02844777 2023-01-12
Efficacy and Safety of VDA-1102 Ointment in the Treatment of Actinic Keratosis
Vidac Pharma
Phase 2 Completed
NCT03006185 2022-09-28
Laser and Microdermabrasion Before Photodynamic Therapy for Actinic Keratoses in Field-cancerized Skin
Bispebjerg Hospital
Phase 2 Completed
NCT03538951 2022-08-23
Phase2b
Vidac Pharma
Phase 2 Completed
NCT04140292 2022-06-24
Vitamin D Supplementation as a Neoadjuvant for Photodynamic Therapy of Actinic Keratoses
Case Comprehensive Cancer Center
Phase 2 Completed
NCT04085367 2022-04-01
Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the Face
Galderma R&D
Phase 3 Completed
NCT01525329 2022-03-15
Combination Therapy With 5-Fluorouracil and Photodynamic Therapy in Post-transplant Premalignant Skin Disease
The Cleveland Clinic
Phase 3 Terminated
NCT02866695 2022-03-09
Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients
University of California, San Francisco
Phase 4 Completed
NCT03322293 2022-03-09
Daylight Photodynamic Therapy for Actinic Keratosis
University of California, San Francisco
Phase 1 Completed
NCT04319159 2021-11-11
Study to Evaluate the Safety of BF-200 ALA (Ameluz®) for Photodynamic Therapy (PDT) in the Treatment of Expanded Fields of Actinic Keratosis (AK)
Biofrontera Bioscience GmbH
Phase 1 Completed
NCT02385318 2021-11-02
To Compare Safety and Efficacy of Perrigo's Drug Product Compared to an FDA Approved Drug Product in the Treatment of Actinic Keratosis
Padagis LLC
Phase 3 Completed
NCT02459795 2021-11-02
To Compare Safety and Efficacy of Perrigo's Drug Compared to an FDA Approved Drug in the Treatment of Actinic Keratosis
Padagis LLC
Phase 3 Completed
NCT01000636 2021-05-26
Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® Photodynamic Therapy (PDT)
Galderma R&D
Phase 4 Completed
NCT02838628 2021-04-14
Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp
Almirall, S.A.
Phase 2 Completed
NCT03285477 2021-04-13
AK003
Almirall, S.A.
Phase 3 Completed
NCT03285490 2021-03-10
A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)
Almirall, S.A.
Phase 3 Completed
NCT01475071 2021-02-18
CoMet
Galderma R&D
Phase 3 Completed
NCT01821391 2021-02-18
COMET2
Galderma R&D
Phase 3 Completed
NCT03511326 2021-02-18
SESAME 2
Galderma R&D
Phase 4 Completed
NCT03914417 2021-01-20
Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream
Icahn School of Medicine at Mount Sinai
Phase 2 Completed